Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists.
Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Greece. Electronic address: stergios@endo.gr.
Stergios A
SA
Polyzos
Division of Gastroenterology, Department of Medical Sciences, University of Torino, Italy.
Elisabetta
E
Bugianesi
Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Greece.
Jannis
J
Kountouras
Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA.
Christos S
CS
Mantzoros
D000818:Animals; D035843:Biomedical Research / Q000379:methods / Q000639:trends; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D008024:Ligands; D008082:Lipotropic Agents / Q000009:adverse effects / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000209:etiology / Q000517:prevention & control*; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D000077205:Pioglitazone; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use
D007004:Hypoglycemic Agents; C541917:INT 131; D008024:Ligands; D008082:Lipotropic Agents; D047495:PPAR gamma; D011804:Quinolines; D013449:Sulfonamides; D045162:Thiazolidinediones; D000077205:Pioglitazone